Mereo BioPharma
1 Cavendish Place
London
W1G 0QF
United Kingdom
Tel: 44-0-333-0237-300
Website: http://www.mereobiopharma.com/
About Mereo BioPharma
Mereo is a UK-based specialty biopharma company established to address the R&D and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo’s business model brings clear benefits to these companies, to investors, and to patients.YEAR FOUNDED:
2015
LEADERSHIP:
Co-Founder and CEO: Dr. Denise Scots-Knight
CFO and COO: Richard Bungay
Co-Founder and GC: Charles Sermon
Co-Founder and CMO: Dr. Alastair MacKinnon
Co-Founder and Head of Corporate Development: John Richard
PIPELINE:
Please click here for Mereo's pipeline.
72 articles with Mereo BioPharma
-
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
11/8/2022
Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm GMT / 07:55am ET.
-
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
10/28/2022
Mereo to Appoint Four New Directors to its Board of Directors.
-
Mereo and Rubric Capital Management settled their proxy battle, entering a cooperation agreement. As a result, Rubric withdrew its notice for a General Meeting of shareholders.
-
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
10/24/2022
Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD).
-
The proxy battle between Mereo BioPharma and Rubric Capital Management will come to a head on Nov. 18. Mereo issued a shareholder circular on Friday.
-
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
10/21/2022
Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced it has filed and mailed a shareholder circular (the “Shareholder Circular”) and related meeting and proxy materials in connection with its upcoming General Meeting of Shareholders (the “General Meeting”) to be held on November 18, 2022 at 2:00 p.m. London time.
-
Mereo BioPharma will cut 40% of its headcount and significantly reduce expenses to support the advancement of its lead programs through the clinic.
-
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
10/18/2022
Mereo BioPharma Group plc today provided an update to its operating plan and programs.
-
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
10/17/2022
Mereo BioPharma Group plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966).
-
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five
10/3/2022
Rubric Capital Management LP, an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc, issued an open letter to Mereo’s shareholders.
-
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
10/3/2022
Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, confirmed that it has received a valid notice from Rubric Capital Management LP under section 303 of the Companies Act 2006 requiring the Board to convene a General Meeting of Shareholders of Mereo.
-
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors
9/12/2022
Mereo BioPharma Group plc reported updated clinical data and promising biomarker data from ACTIVATE, a Phase 1b/ 2 study of anti-TIGIT antibody, etigilimab, in combination with nivolumab, in select recurrent advanced / metastatic solid tumors.
-
Mereo BioPharma Sends Letter to Rubric Capital Management
8/22/2022
Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, sent a letter to Rubric Capital Management LP responding to a letter from Rubric dated August 19, 2022, in which Rubric purported to call for a General Meeting of Shareholders of Mereo and proposed to remove four of Mereo’s directors and replace them with four directors nominated by Rubric.
-
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
7/5/2022
Mereo BioPharma Group plc announced that it has received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market, LLC informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450 and the matter is closed.
-
AstraZeneca appears to have taken an interest in Mereo BioPharma and may be considering a buyout, according to speculations published by The Times UK.
-
Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
6/2/2022
Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE).
-
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
5/26/2022
Mereo BioPharma Group plc announced that on May 23, 2022, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC notifying the Company that its American Depositary Shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of Nasdaq.
-
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
5/26/2022
Mereo BioPharma Group plc announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.
-
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
5/17/2022
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company’s Board of Directors, effective immediately.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.